Abstract
Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Current Molecular Medicine
Title:Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Volume: 14 Issue: 7
Author(s): P. Vanichakarn, J. Hwa and J. Stitham
Affiliation:
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Abstract: Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Export Options
About this article
Cite this article as:
Vanichakarn P., Hwa J. and Stitham J., Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115517
DOI https://dx.doi.org/10.2174/1566524014666140811115517 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature
Current Pharmaceutical Design Genetic Basis of Ureterocele
Current Genomics Role of 2-Antiplasmin in Cardiovascular System
Letters in Drug Design & Discovery Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules
Current HIV Research Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Oxidative Stress in Cerebral Small Vessel Disease Dizziness Patients, Basally and After Polyphenol Compound Supplementation
Current Molecular Medicine Putative Role for Apelin in Pressure/Volume Homeostasis and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes and Gestational Hypertension
Current Hypertension Reviews Inflammation in Hypertension: Current Therapeutic Approaches
Current Pharmaceutical Design Extract of <i>Moringa concanensis</i> Nimmo Leaves Ameliorates Hyperglycemia and Oxidative Stress, and Improves β-cell Function in Alloxan Monohydrate Induced Diabetic Rats
Current Bioactive Compounds Will Sodium Intake Reduction Improve Cardiovascular Outcomes in the General Population? A Critical Review of Current Evidence
Current Hypertension Reviews Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Resveratrol: A Therapeutic Approach to Neurodegenerative Diseases and Aging
Mini-Reviews in Organic Chemistry Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Current Neuropharmacology Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design